BiotechTube

Epcoritamab + Ibrutinib

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Recurrent Diffuse Large B-Cell Lymphoma

Conditions

Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma

Trial Timeline

Apr 2, 2025 → Dec 31, 2028

NCT ID
NCT06536049

About Epcoritamab + Ibrutinib

Epcoritamab + Ibrutinib is a phase 1/2 stage product being developed by AbbVie for Recurrent Diffuse Large B-Cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06536049. Target conditions include Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements.

What happened to similar drugs?

6 of 20 similar drugs in Recurrent Diffuse Large B-Cell Lymphoma were approved

Approved (6) Terminated (0) Active (14)
✅Zopapogene imadenovec (Zopa)PrecigenApproved
✅Bevacizumab + Capecitabine + Everolimus + ExemestaneNovartisApproved
✅FamciclovirNovartisApproved
✅FamciclovirNovartisApproved
✅Pidotimod + PlaceboAlmirallApproved
✅BaclofenBrain BiotechApproved
🔄Rilonacept + PlaceboKiniksa PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
9
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06536049Phase 1/2Recruiting

Competing Products

20 competing products in Recurrent Diffuse Large B-Cell Lymphoma

See all competitors
ProductCompanyStageHype Score
Doxorubicin Hydrochloride Liposome InjectionDr. Reddy's LaboratoriesPhase 1
26
KPL-914Kiniksa PharmaceuticalsPhase 2
29
KPL-387Kiniksa PharmaceuticalsPhase 2
36
Rilonacept + PlaceboKiniksa PharmaceuticalsPhase 3
34
Enzastaurin (LY317615) + CarboplatinEli LillyPhase 1
29
Zopapogene imadenovec (Zopa)PrecigenApproved
44
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2PrecigenPhase 1/2
30
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
Ramucirumab + PembrolizumabEli LillyPhase 2
39
Gemcitabine and UFTE chemotherapyYuhanPhase 2
35
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + PembrolizumabDaiichi SankyoPhase 1/2
39
Ifinatamab deruxtecanDaiichi SankyoPhase 2
42
Trastuzumab DeruxtecanDaiichi SankyoPhase 1
36
PLX3397Daiichi SankyoPhase 2
27
erlotinib + etoposideAstellas PharmaPhase 2
27
Drug Combination TherapySun PharmaceuticalPhase 2
42
Niraparib + AnlotinibSun PharmaceuticalPhase 2
35
Eribulin MesylateEisaiPre-clinical
26
Lenvatinib + EverolimusEisaiPhase 1/2
32
E7090EisaiPhase 2
42